LH
Labcorp Holdings Inc.
NYSE · Healthcare · Medical - Equipment & Services · US
$326.81
−1.41%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 14.3B | 14.0B | 13.0B | 12.2B | 11.9B |
| Cost of Revenue | 10.4B | 10.2B | 9.4B | 8.8B | 8.2B |
| Gross Profit | 4.0B | 3.7B | 3.6B | 3.4B | 3.7B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | 2.0M | — |
| SG&A Expense | 2.2B | 2.2B | 2.2B | 2.0B | 2.0B |
| General & Admin Expense | 577.2M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 159.3M | — | 307.7M | 615.9M | 275.8M |
| Total Operating Expenses | 2.4B | 2.2B | 2.5B | 2.6B | 2.3B |
| Cost and Expenses | 12.7B | 12.4B | 11.9B | 11.4B | 10.4B |
| Operating Income (EBIT) | 1.6B | 1.5B | 1.1B | 725.6M | 1.4B |
| Non-Operating | |||||
| Interest Income | 21.3M | 15.2M | — | — | — |
| Interest Expense | 227.2M | 224.1M | 208.3M | 199.6M | 179.8M |
| Net Interest Income | (205.9M) | (208.9M) | (208.3M) | (199.6M) | (179.8M) |
| Other Non-Op Income/Expense | (383.7M) | (408.7M) | (127.2M) | (156.7M) | (199.1M) |
| Non-Operating Income (excl Interest) | 162.1M | 184.6M | (81.1M) | (42.9M) | 19.3M |
| EBT (Pre-Tax Income) | 1.2B | 1.1B | 959.5M | 568.9M | 1.2B |
| Income Tax Expense | 230.2M | 229.8M | 212.4M | 188.5M | 233.9M |
| Bottom Line | |||||
| Net Income | 1.0B | 876.5M | 746.0M | 418.0M | 1.3B |
| Earnings from Cont. Ops | 1.0B | 877.7M | 747.1M | 380.4M | 1.0B |
| Earnings from Discont. Ops | — | — | — | 38.8M | 277.1M |
| Bottom Line Net Income | 1.0B | 876.5M | 746.0M | 418.0M | 1.3B |
| Per Share | |||||
| Basic EPS | $12.17 | $10.54 | $8.89 | $4.80 | $14.04 |
| Diluted EPS | $12.09 | $10.46 | $8.84 | $4.77 | $13.96 |
| Revenue Per Share | $175.62 | $167.69 | $155.05 | $139.63 | $130.23 |
| Shares | |||||
| Basic Shares Outstanding | 81.7M | 83.2M | 83.9M | 87.1M | 91.1M |
| Diluted Shares Outstanding | 82.0M | 83.8M | 84.4M | 87.6M | 91.6M |
| Profitability Metrics | |||||
| EBITDA | 2.2B | 2.0B | 1.8B | 1.3B | 2.0B |
| D&A | 696.3M | 681.1M | 643.5M | 577.3M | 537.2M |
| EBIT | 1.5B | 1.3B | 1.2B | 768.5M | 1.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026